Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1985-10-18
1987-03-31
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514913, A61K 3150, A61K 31495
Patent
active
046543457
ABSTRACT:
Lyophylisates comprising bromocriptine or an acid addition salt thereof capable of reconstitution in an isotonic vehicle to provide a stable formulation for occular instillation, useful e.g. in the treatment of glaucoma. Typical lyophylisates in accordance with the invention comprise: a lyophylisable acid, e.g. methane sulfonic acid, an acid addition salt of bromocriptine with said acid, e.g. bromocriptine mesylate, benzalkonium chloride and a lyophylisate matrix material.
REFERENCES:
patent: 4091099 (1978-05-01), Fehr et al.
patent: 4219555 (1980-08-01), Rucman et al.
patent: 4462983 (1984-07-01), Azria et al.
patent: 4486416 (1984-12-01), Soll et al.
patent: 4547500 (1985-10-01), Bolliger et al.
The Theory and Practice of Industrial Pharmacy-2nd ed. pp. 521-524 (1976)--Lea & Febiger-Philadelphia, Pa.
Chem. Abst. 69:61505q (1968)--Marso.
Chem. Abst. 99:980p (1983)--Nistico et al.
Chem. Abst. 100:114,972g (1984)--Mekki et al.
Honor Robert S.
Jewell Walter F.
Robinson Douglas W.
Sandoz Ltd.
Sharkin Gerald D.
LandOfFree
Occular formulation comprising bromocriptine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Occular formulation comprising bromocriptine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Occular formulation comprising bromocriptine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213063